CVS Health price target lowered to $100 from $110 at Barclays

Barclays lowered the firm’s price target on CVS Health to $100 from $110 and keeps an Overweight rating on the shares. The analyst updated the model following the close of the Signify acquisition, taking a more conservative stance on buybacks overall given the company’s other large pending acquisitions.